SCHEMBL7424613

SCHEMBL7424613

CCCc1ncc(C(=O)O)[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.48
PIN1 Q13526 1/20 0.43
MMP13 P45452 4/20 0.41
MMP9 P14780 3/20 0.41
BRS3 P32247 2/20 0.39
HCAR2 Q8TDS4 1/20 0.39
KDM5B Q9UGL1 4/20 0.38
KDM6B O15054 3/20 0.38
KDM4A O75164 3/20 0.38
KDM4D Q6B0I6 3/20 0.38
KDM3B Q7LBC6 3/20 0.38
HIF1AN Q9NWT6 3/20 0.38
KDM2A Q9Y2K7 3/20 0.38
KDM5A P29375 1/20 0.38
GLA P06280 1/20 0.37
MMP1 P03956 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27374286 0.89 BRS3 (0.47) MMP2PIN1MMP13MMP9BRS3
SCHEMBL4506135 0.85 PIN1 (0.46) MMP2PIN1MMP13MMP9HCAR2
SCHEMBL27394755 0.84 MMP2 (0.43) MMP2MMP13MMP9BRS3GLA
SCHEMBL4908556 0.81 MMP2 (0.44) MMP2PIN1MMP13MMP9BRS3
SCHEMBL8653203 0.81 MMP2 (0.67) MMP2MMP13MMP9BRS3GLA
SCHEMBL14012152 0.78 PIN1 (0.43) MMP2PIN1MMP13MMP9HCAR2
SCHEMBL9938772 0.77 MMP2 (0.71) MMP2PIN1MMP13MMP9BRS3
SCHEMBL1422384 0.77 MMP2 (0.48) MMP2PIN1MMP13MMP9BRS3
SCHEMBL20630518 0.77 PIN1 (0.46) MMP2PIN1MMP13MMP9HCAR2
SCHEMBL12821931 0.76 MMP13 (0.44) MMP2PIN1MMP13MMP9HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102351849-B Preparation method of olmesartan medoxomil QILU TIANHE PHARMACEUTICAL CO LTD 2013-10-02 CN claimed
CN-102070533-A New method for synthesizing 4-(1-hydroxyl-1-methyl ethyl)-2-propyl imidazole-5-carboxylic acid ethyl ester SHANGHAI SYNCORES TECHNOLOGIES INC 2011-05-25 CN claimed
CN-109081812-A 4- (1- hydroxyl -1- Methylethyl) -2- propyl imidazole -5- carboxylic acid, ethyl ester monohydrate 黄冈鲁班药业股份有限公司 2018-12-25 CN disclosed
CN-106749195-A A kind of olmesartan medoxomil intermediate impurities synthesis, the method for identification 青岛黄海制药有限责任公司 2017-05-31 CN disclosed
CN-104356069-B The preparation method and application of olmesartan medoxomil intermediate 4-(1-hydroxyl-1-Methylethyl)-2-propyl imidazole-5-carboxylic acid, ethyl ester 黄冈鲁班药业有限公司 2016-09-14 CN disclosed
CN-102070533-A New method for synthesizing 4-(1-hydroxyl-1-methyl ethyl)-2-propyl imidazole-5-carboxylic acid ethyl ester SHANGHAI SYNCORES TECHNOLOGIES INC 2011-05-25 CN disclosed
CN-1056140-C Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease SANKYO CO (JP) 2000-09-06 CN disclosed
EP-0986562-A1 SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS MERCK SHARP & DOHME LTD. (GB) 2000-03-22 EP disclosed
WO-1998050385-A1 SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1998-11-12 WO disclosed
WO-1997016192-A1 MUSCARINE ANTAGONISTS MERCK & CO., INC. (US) 1997-05-09 WO disclosed
EP-0748315-A1 USE OF IMIDAZOLE DERIVATIVES FOR TREATING DISORDERS INVOLVING ANGIOTENSIN RECEPTORS AT 1? AND AT 2?, CERTAIN SUCH PRODUCTS, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME ROUSSEL UCLAF (FR) 1996-12-18 EP disclosed
CN-1095374-A Biphenyl derivatives, their preparation and they are in the application for the treatment of hypertension and cardiac disease SANKYO CO (JP) 1994-11-23 CN disclosed
CN-1065063-A 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1992-10-07 CN disclosed